Search

Your search keyword '"Valerie W, Rusch"' showing total 89 results

Search Constraints

Start Over You searched for: Author "Valerie W, Rusch" Remove constraint Author: "Valerie W, Rusch" Publisher american association for cancer research (aacr) Remove constraint Publisher: american association for cancer research (aacr)
89 results on '"Valerie W, Rusch"'

Search Results

1. Systemic and Oligo-Acquired Resistance to PD-(L)1 Blockade in Lung Cancer

2. Data from Integrative Molecular Characterization of Malignant Pleural Mesothelioma

3. Table S3 from Integrative Molecular Characterization of Malignant Pleural Mesothelioma

4. Data from Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer

5. Table S5 from Integrative Molecular Characterization of Malignant Pleural Mesothelioma

6. Figure S2 from Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer

7. Figure S1 from Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer

8. Supplementary Figure 4 from Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies

9. Table S6 from Integrative Molecular Characterization of Malignant Pleural Mesothelioma

10. Table S7 from Integrative Molecular Characterization of Malignant Pleural Mesothelioma

11. Supplementary Figure 1 from Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies

12. Supplementary Figure 6 from Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies

13. Supplementary tables S1-4 from Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies

14. Supplementary Figure Legends from Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer

15. Figure S3 from Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer

16. Supplementary Tables from A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab

17. Supplementary Figure 5 from Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies

18. Table S1 from Integrative Molecular Characterization of Malignant Pleural Mesothelioma

19. Supplementary Figure 2 from Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies

20. Supplementary Figure 7 from Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies

21. Data from A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab

22. Table S2 from Integrative Molecular Characterization of Malignant Pleural Mesothelioma

23. Figure S4 from Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer

24. Tables S1-S5 from Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer

25. Supplementary Figure 3 from Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies

26. Supplementary Data from Integrative Molecular Characterization of Malignant Pleural Mesothelioma

27. Table S4 from Integrative Molecular Characterization of Malignant Pleural Mesothelioma

28. Supplementary Figures from A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab

29. Supplementary Material from A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab

30. Data from Prognostic Immune Markers in Non–Small Cell Lung Cancer

31. Data from Mesothelin Overexpression Promotes Mesothelioma Cell Invasion and MMP-9 Secretion in an Orthotopic Mouse Model and in Epithelioid Pleural Mesothelioma Patients

32. Table S3 from Comprehensive Next-Generation Sequencing Unambiguously Distinguishes Separate Primary Lung Carcinomas From Intrapulmonary Metastases: Comparison with Standard Histopathologic Approach

33. Supplementary Data from Analysis of Tumor Genomic Pathway Alterations Using Broad-Panel Next-Generation Sequencing in Surgically Resected Lung Adenocarcinoma

34. Supplemental Tables from Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular Subtypes

35. Supplementary Figures from KRASG12C Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma

36. Supplemental Methods 2 from Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular Subtypes

38. Data from Tissue and Serum Mesothelin Are Potential Markers of Neoplastic Progression in Barrett's Associated Esophageal Adenocarcinoma

40. Data from Analysis of Tumor Genomic Pathway Alterations Using Broad-Panel Next-Generation Sequencing in Surgically Resected Lung Adenocarcinoma

41. Supplementary Table 1 from A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma

43. Supplementary Data from Comprehensive Genomic Analysis Reveals Clinically Relevant Molecular Distinctions between Thymic Carcinomas and Thymomas

44. Supplemental Figure 1 from Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular Subtypes

45. Supplementary Figure 1 from Mesothelin Overexpression Is a Marker of Tumor Aggressiveness and Is Associated with Reduced Recurrence-Free and Overall Survival in Early-Stage Lung Adenocarcinoma

46. Supplemental Figure 3 from Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular Subtypes

48. Supplementary Figure 2 from Mesothelin Overexpression Is a Marker of Tumor Aggressiveness and Is Associated with Reduced Recurrence-Free and Overall Survival in Early-Stage Lung Adenocarcinoma

50. Supplemental Methods 1 from Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular Subtypes

Catalog

Books, media, physical & digital resources